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Abstract
Introduction: The reduction of the inflammatory status represents one of the most important targets in
rheumatoid arthritis (RA). A central role of A2A and A3 adenosine receptors (ARs) in mechanisms of inflammation
has been reported in different pathologies. The primary aim of this study was to investigate the A2A and A3ARs
and their involvement in RA progression measured by Disease Activity Score in 28 or 44 joints (DAS28 or DAS).
Methods: ARs were analyzed by saturation binding assays, mRNA and Western blotting analysis in lymphocytes
from early and established RA patients. The effect of A2A and A3AR agonists in nuclear factor kB (NF-kB) pathway
was evaluated. Tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-6) release was carried
out by A2A and A3AR activation. AR pharmacological regulation in matrix metalloproteinase-1 (MMP-1) and
metalloproteinase-3 (MMP-3) release was also studied.
Results: In lymphocytes obtained from RA patients, A2A and A3ARs were up-regulated if compared with healthy
controls. A2A and A3AR activation inhibited the NF-kB pathway and diminished inflammatory cytokines such as
TNF-a, IL-1b and IL-6. A2A and A3AR agonists mediated a reduction of MMP-1 and MMP-3 release. A2A and A3AR
density inversely correlated with DAS28 and DAS suggesting a direct role of the endogenous activation of these
receptors in the control of RA joint inflammation.
Conclusions: Taken together these data demonstrate that the inflammatory and clinical responses in RA are
regulated by A2A and A3ARs and support the use of A2A and/or A3AR agonists as novel and effective
pharmacological treatment in RA patients.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease characterized by progressive joint destruction
associated with synovial proliferation and secretion of
high levels of pro-inflammatory mediators, including
cytokines and growth factors [1,2]. Early diagnosis and
therapy are crucial in order to prevent unfavorable
outcome with joint deterioration and functional disabil-
ity [3]. Therapeutic strategies are primarily based on dis-
ease modifying anti-rheumatic drugs (DMARDs) alone
or in combination with biological drugs, in case of
inadequate response. This represents the most innova-
tive and effective treatment to slow the progression of
the disease [4,5]. To date, rheumatologists have widely
adopted the 28-joint Disease Activity Score (DAS28) or
44-joint Disease Activity Score (DAS) as validated and
reliable composite indexes to assess RA disease activity
[6-8].
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cing and permanent degradation of the cartilage with
synovial hyperplasia, change in underlying bone and
high levels of inflammatory mediators [9,10]. It is widely
accepted that cytokines such as tumor necrosis factor-a
(TNF-a), the interleukin-1 (IL-1) family and interleukin-
6 (IL-6) have various important activities in the context
of the RA pathogenesis [11]. In particular, IL-6 interacts
in complex ways with the cells involved in bone remo-
delling indirectly, promoting osteoclastogenesis and con-
tributing to the severity of the radiological joint damage
[12]. Many proteinases are expressed in joint tissues of
RA patients even if among them different matrix metal-
loproteinases (MMPs) are believed to have a key role in
joint destruction [13]. Of these, MMP-1 and MMP-3 are
particularly important because they are produced by
fibroblast-like synoviocytes and monocytes/macrophages
in the synovium and are known to play a key role in tis-
sue destruction [14,15].
Several papers report a central role of adenosine recep-
tors (ARs) in mechanisms of inflammation associated to
various pathologies suggesting that their stimulation has
a different effect on the release of several pro-inflamma-
tory cytokines [16-18]. Adenosine, a purine nucleoside, is
considered a potent regulator acting with four cell sur-
face receptor subtypes - A1,A 2A,A 2B and A3ARs, which
are coupled to different G proteins [19,20]. The A1 and
A3ARs exert an inhibitory effect on cAMP production
while A2A and A2BARs mediate an increase of cAMP
accumulation [21-24]. In RA patients, adenosine sup-
presses the elevated levels of pro-inflammatory cytokines
such as TNF-a and IL-1b [25,26]. It has also been shown
that A3ARs are over-expressed inp a t i e n t sw i t ha u t o i m -
mune inflammatory diseases, including RA, and that
A3AR pharmacological treatment modulates an improve-
ment in signs and symptoms [27-29].
From this background it is accepted that the release of
various inflammatory mediators in RA patients could be
closely associated with ARs, suggesting their potential
role as therapeutic target and the application of novel
pharmacological approaches in the treatment of RA.
Additional data regarding a possible correlation between
validated disease activity scores, such as DAS28 or DAS,
and AR density could be very important in better ascer-
taining the modulation of joint inflammatory status and,
as a consequence, the disease progression.
In a previous study, our group showed that A2A and A3
ARs are up-regulated in early RA (ERA) patients and after
methotrexate treatment but not in RA patients treated
with anti-TNF-a agents [30]. To confirm these data in a
larger cohort of patients, we have investigated in this study
the presence of A1,A 2A,A 2B and A3ARs by saturation
binding assays, mRNA and Western blotting analysis in
human lymphocytes from RA patients with established
disease more than 12 months and ERA patients with
symptom duration less than 12 months in comparison
with age-matched healthy subjects. The effect of A2A and
A3AR agonists or antagonists in nuclear factor kB (NF-kB)
activation and in the production of proinflammatory cyto-
kines was evaluated. The joint degradation process that is
believed to be largely mediated by proteases has been ana-
lyzed by evaluating the effect of A2A and A3AR agonists
on MMP-1 and MMP-3 production. To shed some light
on the role of ARs in the therapeutic approach, the corre-
lation between A2A and A3AR density expressed as Bmax
values with DAS28 and DAS was explored.
Materials and methods
Patients and control subjects
All patients enrolled in this study were recruited from
the Rheumatology Section, Department of Clinical and
Experimental Medicine, University of Ferrara, Italy. A
total of 95 patients was included and divided into ERA
patients (n = 32) and RA patients (n = 63). ERA patients
were diagnosed according to the following criteria:
symptom duration less than 12 months, synovitis of at
least three joints, morning stiffness occurring of more
than 30 minutes duration and exclusion of other com-
mon causes of arthritis. RA patients with established
disease of more than 12 months fulfilled the American
College of Rheumatology (ACR) 1987 criteria for rheu-
matoid arthritis [31]. All of the ERA patients were fol-
lowed up for an additional 12-month period after which
the ACR criteria were met. The demographic, clinical
and pharmacological details are listed in Table 1.
Disease activity was assessed using the validated
indexes DAS28 and DAS, the Health Assessment Ques-
tionnaire (HAQ) was used to evaluate functional impair-
ment, the anti-cyclic citrullinated peptide (anti-CCP)
and rheumatoid factor (RF) were also checked by using
a second generation ELISA method and nephelometry,
respectively [32-34].
Healthy controls (n = 90), matched for similar age to
the cohort of RA patients, were volunteers from Ferrara
University Hospital Blood Bank. The study was
approved by the local Ethics Committee of the Univer-
sity Hospital of Ferrara and informed consent was
obtained from each participant in accordance with the
principles outlined in the Declaration of Helsinki.
Additional data describing materials and detailed meth-
ods, including human lymphocyte preparation, real time
quantitative polymerase chain reaction (RT-PCR), Wes-
tern blotting, saturation binding experiments and ELISA
are published in the online supplementary material.
Sample collection and human lymphocyte preparation
Lymphocytes were isolated and prepared as previously
described from the peripheral blood of control subjects,
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started no later than three to four hours after the sam-
ples had been taken. The blood was supplemented with
6% (by weight) Dextran T500 solution (Sigma, St Louis,
MO, USA) and erythrocytes were allowed to settle down
for 60 minutes. Leukocytes were pelleted by centrifuga-
tion for 15 minutes at 100 g and the remaining erythro-
cytes were lyzed in distilled water at 4°C. Cells were
pelleted by centrifugation for five minutes at 250 g, sus-
pended in Krebs-Ringer phosphate buffer and layered
onto 10 ml of Fycoll-Hypaque (GE Healthcare, Little
Chalfont, UK). After centrifugation, mononuclear cells
were washed in 0.02 M phosphate-buffered saline at pH
7.2 containing 5 mM MgCl2 and 0.15 mM CaCl2.
Finally, they were decanted into a culture flask and
placed in a humidified incubator (5% CO2)f o r2ha t
37°C. This procedure, aimed at removing monocytes,
which adhere to the culture flasks, resulted in a purified
lymphocyte preparation containing at least 99% small
lymphocytes identified by morphological criteria.
To obtain membrane suspensions, cell fractions were
centrifuged in hypothonic buffer at 20,000 g for 10 min-
utes. The resulting pellet was resuspended in tris HCl
50 mM buffer pH 7.4 containing 2 UI/ml adenosine
deaminase (Sigma) and incubated for 30 minutes at 37°
C. After the incubation the suspension was centrifuged
again at 40,000 g for 10 minutes and the final pellet was
used for radioligand binding assays. The protein concen-
tration was determined by a Bio-Rad method with
bovine albumine as reference standard [30].
Real-Time quantitative polymerase chain reaction
(RT-PCR) experiments
Total cytoplasmic RNA was extracted by the acid guani-
dinium thiocyanate phenol method. Quantitative RT-
PCR assays [22] of A1,A 2A,A 2B and A3AR mRNAs
were carried out using gene-specific fluorescently
labelled TaqMan MGB probe (minor groove binder) in
a ABI Prism 7700 Sequence Detection System (Applied
Biosystems, Warrington, Cheshire, UK). For the RT-
PCR of A1,A 2A,A 2B and A3ARs the Assays-on-
Demand™ Gene expression Products NM 000674, NM
000675, NM 000676 and NM 000677 were used respec-
tively. For the RT-PCR of the reference gene, the endo-
genous control human b-actin kits were used, and the
probe was fluorescent-labeled with VIC™ (Applied Bio-
systems, Monza, Italy).
Western blotting analysis
Human lymphocytes were washed with ice-cold phos-
phate buffer saline containing 1 mM sodium orthovana-
date, 104 mM 4-(2-aminoethyl)-benzenesulfonyl
fluoride, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM
bestatin, 1.5 mM pepstatin A, 1.4 mM E-64 (Sigma).
Then cells were lysed in Triton lysis buffer and the pro-
tein concentration was determined using BCA protein
assay kit (Pierce, Rockford, IL, USA).
Aliquots of total protein sample (50 μg) were analyzed
using antibodies specific for human A1,A 2B,A 2A and
A3ARs (1 μg/ml dilution, Alpha Diagnostic, San Anto-
nio, TX, USA) [22]. Filters were washed and incubated
Table 1 Clinical features and pharmacological treatments in RA patients
Control subjects
(n = 90)
ERA patients
(n = 32)
RA patients
(n = 63)
Clinical parameters
N° of women/N° of men 53/37 28/4 55/8
Age, mean ± SEM years 55.2 ± 6.3 59.2 ± 2.5 62.7 ± 1.3
Duration of RA (mean ± SEM months) - 5.1 ± 0.6 136.7 ± 15.2
Rheumatoid factor positive, RF, N°(%) - 15 (46.9%) 42 (66.7%)
Anti-CCP antibody positive, N°(%) - 14 (43.8%) 43 (68.3%)
DAS28 (mean ± SEM) - 4.85 ± 0.25 4.92 ± 0.18
DAS (mean ± SEM) - 3.44 ± 0.19 3.47 ± 0.14
HAQ (mean ± SEM) - 1.21 ± 0.10 1.32 ± 0.12
Pharmacological treatments n (%) n (%)
NSAIDs - 7 (21.9%) 5 (7.9%)
GC - 19 (59.4%) 27 (42.9%)
GC + DMARDs - 6 (18.8%) 31 (49.2%)
CyA - 1 (3.1%) 0
HCL - 2 (6.3%) 2 (3.2%)
MTX - 3 (9.4%) 19 (30.2%)
LFN - 0 10 (15.9%)
Anti-CCP, anti-cyclic citrullinated peptide; CyA, Cyclosporin A; DAS, Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; ERA, early rheumatoid
arthritis; GC, glucocorticoids low dose, alone; HAQ, healthy assessment questionnaire; HCL, hydroxichloroquine. LFN, leflunomide; MTX, methotrexate; NSAIDs,
nonsteroidal anti-inflammatory drugs; RA, rheumatoid arthritis
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jugated secondary antibodies (1:2,000 dilution). Specific
reactions were revealed with Enhanced Chemilumines-
cence Western blotting detection reagent (GE Health-
care, Little Chalfont, UK).
Saturation binding experiments to A1,A 2A,A 2B and A3ARs
Saturation binding experiments to A1ARs were per-
formed by using (
3H)-DPCPX ((
3H)-1,3-dipropyl-8-
cyclopentyl-xanthine, specific activity 120 Ci/mmol, Per-
kin Elmer Life and Analytical Sciences, Boston, MA,
USA) as radioligand [30]. Human lymphocyte mem-
branes (60 μg of protein/assay) with 8 to 10 concentra-
tions of (
3H)-DPCPX (0.01-20 nM) were incubated for
90 minutes at 25°C. Non-specific binding was deter-
mined in the presence of DPCPX 1 μM.
Saturation binding to A2AARs was carried out with
the use of (
3H)-ZM 241385 ((
3H)-4-(2-(7-amino-2-(2-
furyl)(1,2,4)-triazolo(2,3-a)(1,3,5)triazin-5-ylamino)ethyl)
phenol, specific activity 27 Ci/mmol, Biotrend, Cologne,
Germany), as radioligand [30]. Cell membranes (60 μg
of protein/assay) were incubated for 60 minutes at 4°C
with various concentrations (0.01 to 20 nM) of (
3H)-ZM
241385. Non specific binding was determined in the
presence of ZM 241385 1 μM.
Saturation binding experiments to A2BARs were ana-
lyzed using (
3H)-MRE 2029F20 ((
3H)-N-benzo(1,3)
dioxol-5-yl-2-(5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahy-
dro-1H-purin-8-yl)-1-methy-1H-pyrazol-3-yl-oxy)-aceta-
mide, specific activity 123 Ci/mmol, GE Healthcare,
Little Chalfont, UK) as radioligand [30]. Cell membranes
(80 μg of protein/assay) and (
3H)-MRE 2029F20 (0.01 to
30 nM) were incubated for 60 minutes at 4°C and non-
specific binding was determined in the presence of MRE
2029F20 1 μM.
Saturation binding experiments to A3ARs were
assessed using [
3H]-MRE 3008F20 ((
3H)-5N-(4-methox-
yphenylcarbamoyl) amino-8-propyl-2-(2-furyl) pyrazolo
(4,3-e)-1,2,4-triazolo (1,5-c)pyrimidine, specific activity
67 Ci/mmol, GE Healthcare, UK) as radioligand [30].
The membranes (80 μg of protein/assay) with (
3H)-MRE
3008F20 (0.01 to 30 nM) were incubated at 4°C for 150
minutes and MRE 3008F20 1 μM was used to evaluate
non specific binding.
Bound and free radioactivity was separated by filtering
the assay mixture through Whatman GF/B glass fibre
filters by using a Brandel cell harvester. The filter bound
radioactivity was counted in a 2810 TR liquid scintilla-
tion counter Packard (Perkin Elmer, Boston, MA, USA).
Lymphocyte cell culture
Isolated lymphocytes from controls and RA patients
were suspended at a density of 10
6 cells/ml in RPMI
1640 medium supplemented with 2% fetal bovine serum
(Euroclone, Milan, Italy) and seeded into 24-well plates
(1 ml/well). Cells were allowed to rest for two hours in
a 37°C incubator in 5% CO2/95% air.
Cells were then pre-incubated for 15 minutes with 100
nM of CGS 21680 (4-(2-((6-Amino-9-(N-ethyl-b-D-ribo-
furan uronamidosyl)-9H-purin-2-yl)amino)ethyl)benzene
propanoic, Sigma) or Cl-IB-MECA (N
6-(3-iodo-benzyl)-
2-chloro-adenosine-5’-N-methyluronamide, Sigma) in
the absence and in the presence of selected A2A or
A3AR antagonists. The antagonists used were SCH
442416 (2-(2-Furanyl)-7-(3-(4-methoxyphenyl)propyl)-
7H-pyrazolo(4,3-e)(1,2,4) triazolo(1,5-c)pyrimidin-5-
amine, Tocris, Bristol, UK) or MRS 1334 (1,4-Dihydro-
2-methyl-6-phenyl-4-(phenylethynyl)-3,5-pyridinedicar-
boxylic acid 3-ethyl-5-((3-nitrophenyl)methyl) ester,
Tocris) at 1 μM concentration, respectively. Adenosine
agonists and/or antagonists were incubated before cell
activation with 5 ng/ml phorbol myristate acetate
(PMA) for 24 hours [35]. At the end of incubation the
cell suspension was collected and centrifuged at 1,000 g
for 10 minutes at 4°C. Then, the supernatants or cell
pellets were used for ELISA assays or nuclear extract
preparation, respectively.
NF-kB activation in human cultured lymphocytes
Nuclear extracts from human cultured lymphocytes of
the examined patients were obtained by using a nuclear
extract kit (Active Motif, Carlsbad, CA, USA) according
to the manufacturer’s instructions. The NF-kB activation
was evaluated by detecting phosphorylated p65 proteins
in nuclear extracts by using the TransAM NF-kB kit
(Active Motif). Phosphorylated NF-kB subunits specifi-
cally bind to the immobilized oligonucleotides contain-
ing the NF-kB consensus site (5’-GGGACTTTCC-3’).
The primary antibody used to detect NF-kB recognized
an epitope in the subunits that is accessible only when
it is activated and bound to its DNA target. A horserad-
ish peroxidase (HRP)-conjugated secondary antibody
provided a sensitive colorimetric readout that was quan-
tified by spectrophotometry at 450 nm wavelength [30].
Pro-inflammatory cytokines release in cultured
lymphocytes
TNF-a levels were measured in human cultured lym-
phocytes after the treatment described above by using
highly sensitive TNF-a enzyme linked immunosorbent
assay (R&D Systems, Minneapolis, MN, USA) according
to the manufacturer’s instructions.
Pro-inflammatory cytokine (IL-1b and IL-6) levels
were determined with a quantitative sandwich ELISA kit
(R&D Systems) according to the manufacturer’s instruc-
tions [36]. The reaction was developed with streptavi-
din-horseradish peroxidase and optical density was read
at 450 nm wavelength.
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cultured monocytes
To obtain human monocytes, peripheral blood mono-
nuclear cells were seeded in petri dishes at the density
of 10
6/ml. The cells were allowed to adhere to plastic
tissues and non adherent cells (lymphocytes) were
removed.
In cultured monocytes, MMP levels were measured
after the treatment described above by using the corre-
sponding quantitative sandwich ELISA kit (R&D Sys-
tems,) according to the manufacturer’s instructions [37].
Briefly, the assay systems measure natural and recombi-
nant human active and pro-MMPs (total MMPs).
Statistical analysis
Dissociation equilibrium constants for saturation binding,
affinity or KD values, as well as the maximum densities of
specific binding sites, Bmax were calculated for a system
of one or two-binding site populations by non-linear
curve fitting using the program Ligand purchased from
Kell Biosoft, Ferguson, MO, USA. All data are reported
as mean ± SEM of different independent experiments as
indicated in the Results section or in the Figure legends.
Analysis of data was performed by one-way analysis of
variance (ANOVA). Differences between the groups were
analyzed with Dunnett’s test and were considered signifi-
cant at a value of P < 0.01. A simple regression model
was used to analyze the linear dependence of clinical
variables on Bmax values of A2A and A3ARs.
Results
A2A and A3ARs are up-regulated in RA patients
Figure 1A reports the relative A1,A 2A,A 2B and A3AR
mRNA levels determined by RT-PCR in human lympho-
cytes from healthy subjects, and ERA and RA patients.
Among these receptors only A2A and A3AR mRNA
expression in RA patients was significantly increased.
Western blotting and densitometric analysis in lympho-
cytes indicate a significant increase in A2A and A3AR
protein expression in RA patients compared to healthy
subjects while no differences were found in A1 and
A2BARs (Figure 1B, C).
The affinity (KD, nM) and receptor density (Bmax,
fmol/mg protein) of A1,A 2A,A 2B and A3ARs in lympho-
cyte membranes from healthy control group and RA
patients are reported in Table 2. In lymphocyte mem-
branes, the affinity and density of A1 and A2BARs were
not significantly different in RA patients (ERA and
established), if compared with the control group. The
affinity of the radioligands for A2A and A3ARs in ERA
and RA patients was decreased (*, P < 0.01, Table 2) if
compared with the control group. Moreover, A2A and
A3AR density was significantly increased in ERA and
RA patients compared with healthy subjects (Figure 2).
A2A and A3AR agonists reduce NF-kB activation in RA
Cultured lymphocytes of ERA and RA patients were
characterized by high levels of activated NF-kB p65 in
comparison with control subjects showing 1.5- and 1.6-
fold increase, respectively (Figure 3A). CGS 21680 or
Cl-IB-MECA (100 nM) were able to significantly inhibit
NF-kB levels in the cultured lymphocytes derived from
the subjects investigated. This effect was abolished by
using well-known A2A and A3AR antagonists SCH
442416 and MRS 1334, respectively. The inhibitory
effect mediated by A2A and A3AR agonists in RA
patients was more than in healthy subjects (Figure 3A).
Cytokine release is inhibited by A2A and A3AR stimulation
in RA
The effect of A2A and A3AR agonists and/or antagonists
on TNF-a (Figure 3B), IL-1b (Figure 3C) and IL-6 (Figure
3D) release was studied in lymphocytes. In cultured lym-
phocytes, without endogenous adenosine, obtained from
ERA and RA patients, a marked release of TNF-a was
observed, reaching 2.8- (ERA) and 3.1- (RA) fold of
increase in respect to healthy subjects (Figure 3C). In addi-
tion, the stimulation of A2AAR with CGS 21680 mediated
a significant inhibition of PMA-induced TNF-a release by
63% in ERA or by 62% in RA patients in comparison with
control condition (35%). Similar results were obtained
through the A3AR stimulation by using Cl-IB-MECA at
the 100 nM concentration (60% in ERA, 57% in RA
patients, 28% in healthy subjects). The inhibitory effect of
A2A and A3AR agonists was counteracted by the antago-
nists SCH 442416 and MRS 1334 (1 μM), respectively.
As shown in Figure 3C, D basal levels of IL-1b and
IL-6 released by cultured lymphocytes in RA patients
were more than in controls. In addition, PMA (5 ng/ml)
induced a marked release of these pro-inflammatory
cytokines. The stimulation of A2A and A3ARs resulted
in a significant reduction of IL-1b and IL-6 confirming
their potential anti-inflammatory role in RA patients.
The major effect was obtained in lymphocytes from RA
patients most likely due to the up-regulation of A2A and
A3ARs. A2AAR agonist mediated an inhibition of IL-1b
and IL-6 in ERA (62% and 66%, respectively) or in RA
patients (64% and 67%, respectively) in comparison with
control subjects (Figure 3C). Similar results were
obtained by using A3A Rs t i m u l a t i o no nI L - 1 b (Figure
3C) and on IL-6 release (Figure 3D). The direct involve-
ment of A2A and A3ARs was demonstrated by using
selective antagonists, SCH 442416 and MRS 1334,
respectively, that were able to completely abrogate the
inhibitory effect mediated by the agonists.
A2A and A3ARs reduce MMP secretion in RA
Incubation of monocytes with PMA (5 ng/ml) for 24
hours induced MMP-1 and MMP-3 protein production.
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Figure 1 A1 A2A A2B and A3ARs in RA patients. A) Relative AR mRNA levels determined by RT-PCR in human lymphocytes from ERA (n = 32),
RA patients (n = 63) and control subjects (n = 90). B) Representative Western blotting analysis shows immunoblot signals of ARs in ERA, RA
patients and controls. C) Densitometric analysis of AR expression in human lymphocytes from ERA (n = 32), RA patients (n = 63) and control
subjects (n = 90) indicated as a ratio of b-actin (loading control). Data are expressed as a means ± SEM. *, P < 0.01 vs control group.
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agonists the production of MMP-1 was inhibited in RA
patients more than in healthy subjects (60% or 49% in
ERA, 58% or 49% in RA patients, 37% or 29% in healthy
subjects, respectively) (Figure 3E). Similar results were
obtained evaluating the production of MMP-3 suggest-
ing that these MMPs are closely associated with A2A or
A3AR modulation (Figure 3F). The inhibitory effect of
the A2A and A3AR agonists was blocked by the presence
of selective antagonists demonstrating the direct invol-
vement of these AR subtypes.
A2A and A3AR binding parameters correlate with DAS28
and DAS
An inverse correlation was found between DAS28 and
A2A or A3AR density expressed as Bmax values in fmol/
mg protein (Figure 4A, B). A similar correlation was
also found between DAS and A2A or A3AR density (Fig-
ure 4C, D). No other significant correlation was found
between A2A or A3AR affinity and DAS28 or DAS.
Discussion
The primary aim of this study was to investigate the
involvement of ARs in RA inflammatory responses and
to assess potential relationships between these receptors
and disease activity. In lymphocytes from healthy sub-
jects (n = 90) ARs showed affinity values in the nano-
molar range and a density from 34 to 137 fmol/mg
protein. In ERA patients (n = 32) binding experiments
have revealed a significant decrease of the affinity asso-
ciated with an increase of A2A (3.2-fold) and A3AR (2.1-
fold) density as demonstrated by Bmax values (Table 2).
Similarly in established RA patients (n = 63) an up-regu-
lation of A2A and A3ARs density values was found.
mRNA assays and Western blotting with densitometric
analysis supported that A2A and A3ARs are higher in
RA patients in respect to control subjects. These data
confirmed our previous results obtained in a small
cohort of ERA (n =2 0 )a n dR Ap a t i e n t s( n =2 3 )s h o w -
ing an increased A2A and A3AR density compared with
healthy (n = 30) individuals [30]. In that study our
group found that in RA patients treated with anti-TNF-
a agents, A2A and A3AR density was similar to control
subjects demonstrating an active role of TNF-a in the
up-regulation of these receptors, as was also suggested
by literature data [38-40]. To date, it has been reported
that A3ARs in peripheral blood mononuclear cells of
patients with autoimmune inflammatory diseases, such
as RA, psoriasis and Crohn’s disease, are over-expressed
if compared with healthy subjects [27]. A highly specific
orally bioavailable A3AR agonist, CF101 has been used
in active RA patients where A3ARs are overexpressed in
synovial tissue and in peripheral blood mononuclear
cells [29].
In this report, we verified whether the increase in A2A
and A3AR density was associated with inflammatory cel-
l u l a rr e s p o n s e s ,s u c ha sN F - k B ,T N F - a,I L - 1 b,I L - 6 ,
MMP-1 and MMP-3. The ability of CGS 21680 or Cl-
IB-MECA to inhibit NF-kB activation was studied show-
ing an increase of their effect in ERA and RA patients.
Currently, there is considerable interest in developing
specific alternative pharmacological treatments reducing
NF-kB activation and pro-inflammatory cytokine pro-
duction in RA through the involvement of A2A and
A3ARs [16]. It has been reported that A3AR overexpres-
sion in RA patients induced by inflammatory cytokines
is able to reduce NF-kB activation [41]. The complex
studies performed on NF-kB activation clearly demon-
strated a central role for p65 or p50/p65 heterodimers
in the inflammation that underlies RA [13]. It is well
known that NF-kB positively regulates gene encoding
cytokines, such as TNF-a, IL-1b, IL-6 and other inflam-
matory factors, suggesting that this transcription factor
could be one of the master regulators of inflammatory
Table 2 Adenosine receptor binding parameters in lymphocyte membranes from healthy controls, ERA and RA
patients
(
3H)-DPCPX
A1ARs
(
3H)-ZM 241385
A2AARs
(
3H)-MRE2029F20
A2BARs
(
3H)-MRE3008F20
A3ARs
Healthy
controls
n =9 0
KD = 1.76 ± 0.08
nM
Bmax = 34 ± 2 fmol/mg
protein
KD = 1.41 ± 0.10 nM
Bmax = 58 ± 4
fmol/mg protein
KD = 2.29 ± 0.14 nM
Bmax = 55 ± 3
fmol/mg protein
KD = 1.92 ± 0.09 nM
Bmax = 137 ± 9
fmol/mg protein
ERA
patients
n =3 2
KD = 1.74 ± 0.06
nM
Bmax = 33 ± 2 fmol/mg
protein
KD = 2.09 ± 0.14* nM
Bmax = 185 ± 12* fmol/mg
protein
KD = 2.29 ± 0.10 nM
Bmax = 55 ± 2 fmol/mg
protein
KD = 3.03 ± 0.14* nM
Bmax = 290 ± 15*
fmol/mg protein
RA
patients
n =6 3
KD = 1.69 ± 0.07
nM
Bmax = 35 ± 2 fmol/mg
protein
KD = 1.93 ± 0.12* nM
Bmax = 195 ± 13* fmol/mg
protein
KD = 2.36 ± 0.07 nM
Bmax = 54 ± 2 fmol/mg
protein
KD = 3.47 ± 0.21* nM
Bmax = 328 ± 22* fmol/mg
protein
ERA, early rheumatoid arthritis; KD, affinity constant, nM; Bmax, maximum density of specific binding sites, fmol/mg protein; RA, rheumatoid arthritis. Data are
expressed as mean ± SEM. Differences were considered significant at a value of P < 0.01 vs healthy controls (*).
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Page 7 of 13cytokine production in RA [42]. Animal models of
inflammatory arthritis also support the concept that NF-
kB activation happened prior to the onset of clinical
manifestations of arthritis [43]. In a murine type II col-
lagen-induced arthritis, it was found that NF-kB expres-
sion correlated with MMP-13 and MMP-3 levels leading
to cartilage destruction and articular damage [44].
It was also reported that several cytokines may partici-
pate in the pathogenesis of cartilage damage and TNF-a
represents one of the principal cytokines linked to the
cartilage destruction. In our experimental conditions the
stimulation of A2A and A3ARs reduced the high levels
of TNF-a found in ERA and in RA patients, probably
via an inhibition of NF-kB. These data are in agreement
with previous results showing that the activation of A2A
and A3A R ss u p p r e s s e sp r o i n f l a m m a t o r yc y t o k i n e s
[25,45]. It is well known that different cytokines are
expressed and are functionally active in the synovial tis-
sue or in peripheral blood cells of RA patients [11,46].
We found that the stimulation of A2A and A3ARs
mediated a significant decrease of IL-1b or IL-6 release
in RA patients in comparison with healthy subjects.
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Figure 2 Saturation binding experiments of A2A and A3ARs in RA patients. Saturation curves (left) and Scatchard plots (right) showing the
binding of (
3H)-ZM 241385 to A2AARs (A and B) as well as the binding of (
3H)-MRE 3008F20 to A3ARs (C and D) in lymphocyte membranes
derived from 90 healthy controls (￿), 32 ERA patients (■), 63 RA patients (▲). Saturation binding experiments were performed as described in the
online supplementary material and the data are reported in Table 2.
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Figure 3 Effect of A2A and A3AR stimulation in NF-kB, TNF-a, IL-1b, IL-6, MMP-1 and MMP-3. Effect of a well-known A2AAR agonist and
antagonist (CGS 21680, 100 nM; SCH 442416, 1 μM) or A3AR agonist and antagonist (Cl-IB-MECA, 100 nM; MRS 1334, 1 μM) in cultured
lymphocytes of ERA (n = 30), RA patients (n = 30) and healthy subjects (n = 30) on: NF-kB activation (A) which was evaluated by detecting
phosphorylated p65 proteins in nuclear extracts. The effect of the same compounds was also established in TNF-a release in control conditions
and stimulated by PMA 5 ng/ml (B) and in IL-1b (C) and IL-6 levels (D). The effect of the same compounds in monocytes from ERA, RA patients
and healthy subjects in MMP-1 (E) and MMP-3 (F) activation was investigated. Functional experiments were carried out as described in the
online supplementary material. Values are the mean and SEM. *, P < 0.01 versus controls (A); *, P < 0.01 versus PMA-treated cells (B-F).
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Page 9 of 13These data suggest a direct involvement of adenosine in
the expression of IL-6 that represents a key pro-inflam-
matory cytokine associated with the severity of the joint
damage and osteoclastogenesis [12,47,48].
The destruction of articular cartilage is a typical
pathologic feature of arthritic diseases such as RA
mediated by proteases belonging to MMP class enzymes
[43]. Among these, MMP-1 and MMP-3 are considered
to be of particular interest since they directly degrade
the components of the cartilage matrix, including aggre-
can and collagen [13]. Proinflammatory cytokines, such
as TNF-a and IL-1b, stimulate the production of MMPs
through the activation of cellular signaling pathways
involving NF-kB [42,49]. We have investigated the effect
of A2A and A3AR stimulation on MMP-1 and MMP-3
production showing a significant inhibition in ERA and
RA patients in respect to healthy subjects. In RA
patients, the increase of A2A and A3AR density reflected
an increase in receptor functionality suggesting a role of
adenosine in the reduction of inflammatory status and
in cartilage degradation induced by MMP activity and
expression. These data are in agreement with those
found in studying the inhibitory effect of AR stimulation
on MMP-1 and MMP-3 expression in synovial fibro-
blasts [15,50].
The progression of RA is quite heterogeneous, ranging
from very mild to rapidly progressive and debilitating
forms. To optimize the management of the disease, an
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Figure 4 Correlation between DAS28 or DAS and A2A or A3AR density. Linear regression analysis between DAS28 or DAS and the receptor
density expressed as Bmax (fmol/mg protein) of A2A (A, C) and A3ARs (B, D) in lymphocytes from 32 ERA and 63 RA patients considered as a
whole.
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Page 10 of 13international task force of rheumatologists has recently
delivered recommendations based on the new therapeu-
tic paradigm known as “treat to target”. In this new sce-
nario the close monitoring of DAS28 or DAS aimed to
reach a state of remission, or alternatively a state of low
disease activity, is used by an attending clinician to adjust
pharmacological therapy [51]. At the present time due to
the multifaceted nature of RA, no single clinical or
laboratory parameter is able to describe satisfactorily the
level of inflammatory activity or the disease prognosis at
any given time [8]. Recently, it has been reported that the
presence of a relationship between DAS28 and serum
adenosine deaminase (ADA) levels suggests that ADA
concentration may predict disease activity in RA patients
[52]. Our data, for the first time, show an inverse correla-
tion between disease activity measured by DAS28 or
DAS and A2A or A3AR density confirming a relationship
between the inflammation and adenosine in RA.
Conclusions
This paper suggests a correlation of A2A and A3AR with
the inflammatory and clinical responses in RA and that
their up-regulation could represent a compensatory
mechanism to better counteract the inflammatory status.
In particular, the highest levels of A2A and A3AR density
are closely associated with the lowest levels of DAS28
and DAS, suggesting that the endogenous activation of
these receptors attenuates the disease activity. From the
pharmacological point of view, it could be of crucial
importance that the stimulation of the over-expressed
A2A and A3 ARs leads to the inhibition of cellular pro-
inflammatory and degenerative mediators.
The novel findings of this study are represented by a
high inverse correlation between A2A or A3AR density
and the DAS28 or DAS validated index of disease activ-
ity in RA. Moreover, our results suggest the use of A2A
and/or A3AR agonists as novel potential pharmacologi-
cal treatment combined with the classical therapy in
human diseases characterized by a marked inflammatory
component as in RA.
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